189 related articles for article (PubMed ID: 19111238)
1. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
2. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
3. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
4. [Hepatocellular carcinoma - long-term treatable disease].
FĂnek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
6. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
7. Sorafenib in advanced hepatocellular carcinoma.
Copur MS
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
[No Abstract] [Full Text] [Related]
8. Sorafenib in liver cancer--just the beginning.
Roberts LR
N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
[No Abstract] [Full Text] [Related]
9. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
11. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
12. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Zhu AX
Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
[No Abstract] [Full Text] [Related]
13. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
14. Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Kim DY; Han KH
J Gastroenterol Hepatol; 2011 Nov; 26(11):1585-6. PubMed ID: 22011294
[No Abstract] [Full Text] [Related]
15. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
16. Management of hepatocellular carcinoma: beyond sorafenib.
Chan SL; Mok T; Ma BB
Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
[TBL] [Abstract][Full Text] [Related]
17. Developing better treatments in hepatocellular carcinoma.
Duffy A; Greten T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life and sorafenib.
Spinzi G; Terreni N
Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
[No Abstract] [Full Text] [Related]
19. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW
Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
[No Abstract] [Full Text] [Related]
20. Hepatocellular carcinoma: The beginning of a long journey.
Cascinu S
Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
[No Abstract] [Full Text] [Related]
[Next] [New Search]